The Role of Acute Care Prescribing in the Opioid Epidemic
With the growing changes in healthcare nationally, the delivery of care and best practices are evolving. This particularly pertains to the prescription of opioid medications. The Quality Rounds lecture series is designed to respond to these challenges and practice gaps. Chad Brummett, MD will identify opportunities to deliver excellence in the quality of care and patient safety regarding the prescription of opioid medications throughout Mass General Brigham. Our audience of physicians will bring this knowledge back to their service areas to further the delivery of care for our patients while improving efficiencies and maximizing our resources.
This activity is intended for physicans across the Mass General Brigham system.
Upon completion of this activity, participants will be able to:
- Describe the current state of opioid prescribing & opioid-related mortality
- Discuss the ways in which acute care in surgical, dental and emergency medicine contribute to the opioid crisis
- Describe the ways in which individuals & health systems can positively impact the opioid crisis
Brigham & Women's Hospital & Mass General Brigham
Chad Brummett, MD
Senior Associated Chair of Research
Bert N. LaDu Professor of Anesthesiology
Division of Pain Medicine
University of Michigan Medical School
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Mass General Brigham designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Summary of Relevant Financial Relationships
Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE) activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.
The following planners have reported no relevant financial relationship with an ineligible company:
Scott G. Weiner, MD, MPH
The following speakers have reported relevant financial relationships an ineligible company:
Chad Brummett, MD
Investigator: NIH Common Fund, NIAMS/NIH, NIDA/NIH, Michigan Department of Health & Human Services, SAMHSA, CDC, Precision Health Initiative
Consultant: Heron Therapeutics, Vertex Pharmaceuticals, Benter Foundation, Alosa Health, Expert Testimony
Advisory Board: Heron Therapeutics, Vertex Pharmaceuticals, Benter Foundation, Alosa Health, Expert Testimony
Patent: peripheral perineural dexmedetomidine alone/local anesthetics (application #12/791, patent #8410140)
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation